波士顿科学公司(Boston Scientific Scientific Science)比预期的收益更高,但由于法律风险和CEO股价的出售,股票下跌。 Boston Scientific beat earnings expectations but saw stock drop due to legal risks and CEO’s share sale.

波士顿科学社报告说,2026年2月4日的收入比预期的要好,每年收入分别为0.80 EPS和52.9亿美元,比预期增加15.9%。 Boston Scientific reported better-than-expected earnings on February 4, 2026, with $0.80 EPS and $5.29 billion in revenue, a 15.9% year-over-year increase. 该公司将其股票回购授权提高到50亿美元,表明对其财政实力的信心。 The company raised its share buyback authorization to $5 billion, signaling confidence in its financial strength. 尽管取得了积极成果,并更新了全年指导,但股票在未结集体诉讼诉讼和CEO股份销售的法律不确定性中,收益后价值下降了6%。 Despite positive results and upgraded full-year guidance, the stock dropped 6% post-earnings amid legal uncertainty from pending class action lawsuits and a CEO share sale. 包括Vinva投资管理公司和Rhenman & Partners在内的机构投资者增加了他们的股权,而该公司的市场上限为1 057.1亿美元,分析家维持了“机动购买”共识,目标为108.36美元。 Institutional investors, including Vinva Investment Management and Rhenman & Partners, increased their stakes, while the firm’s market cap stands at $105.71 billion and analysts maintain a "Moderate Buy" consensus with a $108.36 target.